CONMED Corporation Cash Flow Conversion Efficiency
CONMED Corporation cash flow conversion efficiency. Based on the latest financial reports, CONMED Corporation (CNMD) has a cash flow conversion efficiency ratio of 0.013x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($13.47 Million) by net assets ($1.02 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of CONMED Corporation (1990–2025)
Cash flow conversion efficiency of CONMED Corporation from 1990 to 2025. This chart illustrates how CONMED Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CNMD live share price for real-time trading data and today's change.
CONMED Corporation Cash Flow Conversion Ratio Explained
CONMED Corporation cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
CONMED Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CONMED Corporation ranked by their cash flow conversion efficiency. Also see CONMED Corporation market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nabors Industries Ltd.
NYSE:NBR
|
0.094x |
|
Paras Defence and Space Technologies Limited
NSE:PARAS
|
-0.019x |
|
Green Cross Corp
KO:006280
|
0.094x |
|
Lumexa Imaging Holdings, Inc. Common Stock
NASDAQ:LMRI
|
0.053x |
|
Smartgroup Corporation Ltd
AU:SIQ
|
0.253x |
|
Taiyuan Heavy Industry Co Ltd
SHG:600169
|
0.080x |
|
Five Star Bancorp
NASDAQ:FSBC
|
0.050x |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
|
0.015x |
Annual Cash Flow Conversion Efficiency for CONMED Corporation (1990–2025)
The table below shows the annual cash flow conversion efficiency of CONMED Corporation from 1990 to 2025. Review CNMD cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.03 Billion | $170.69 Million | 0.165x | -4.74% |
| 2024-12-31 | $962.68 Million | $166.97 Million | 0.173x | +15.43% |
| 2023-12-31 | $834.22 Million | $125.35 Million | 0.150x | +235.75% |
| 2022-12-31 | $745.54 Million | $33.37 Million | 0.045x | -68.55% |
| 2021-12-31 | $785.43 Million | $111.77 Million | 0.142x | +56.36% |
| 2020-12-31 | $709.04 Million | $64.53 Million | 0.091x | -32.03% |
| 2019-12-31 | $710.47 Million | $95.13 Million | 0.134x | +18.71% |
| 2018-12-31 | $662.27 Million | $74.70 Million | 0.113x | +8.63% |
| 2017-12-31 | $631.43 Million | $65.57 Million | 0.104x | +57.72% |
| 2016-12-31 | $580.58 Million | $38.22 Million | 0.066x | -19.87% |
| 2015-12-31 | $585.07 Million | $48.07 Million | 0.082x | -26.72% |
| 2014-12-31 | $581.30 Million | $65.18 Million | 0.112x | -16.02% |
| 2013-12-31 | $606.32 Million | $80.95 Million | 0.134x | -14.87% |
| 2012-12-31 | $607.00 Million | $95.20 Million | 0.157x | -12.73% |
| 2011-12-31 | $573.07 Million | $102.99 Million | 0.180x | +175.65% |
| 2010-12-31 | $586.56 Million | $38.24 Million | 0.065x | +50.18% |
| 2009-12-31 | $576.51 Million | $25.03 Million | 0.043x | -62.25% |
| 2008-12-31 | $531.73 Million | $61.15 Million | 0.115x | -11.87% |
| 2007-12-31 | $505.00 Million | $65.89 Million | 0.130x | -11.02% |
| 2006-12-31 | $440.35 Million | $64.57 Million | 0.147x | +56.54% |
| 2005-12-31 | $453.01 Million | $42.43 Million | 0.094x | -43.93% |
| 2004-12-31 | $447.98 Million | $74.84 Million | 0.167x | +24.84% |
| 2003-12-31 | $433.49 Million | $58.01 Million | 0.134x | +15.27% |
| 2002-12-31 | $386.94 Million | $44.92 Million | 0.116x | -57.32% |
| 2001-12-31 | $283.63 Million | $77.15 Million | 0.272x | +74.48% |
| 2000-12-31 | $230.60 Million | $35.95 Million | 0.156x | -10.97% |
| 1999-12-31 | $211.30 Million | $37.00 Million | 0.175x | +51.93% |
| 1998-12-31 | $182.20 Million | $21.00 Million | 0.115x | -41.03% |
| 1997-12-31 | $162.70 Million | $31.80 Million | 0.195x | +19.69% |
| 1996-12-31 | $158.60 Million | $25.90 Million | 0.163x | +140.15% |
| 1995-12-31 | $75.00 Million | $5.10 Million | 0.068x | -64.69% |
| 1994-12-31 | $43.10 Million | $8.30 Million | 0.193x | +26.69% |
| 1993-12-31 | $37.50 Million | $5.70 Million | 0.152x | +63.40% |
| 1992-12-31 | $38.70 Million | $3.60 Million | 0.093x | +125.91% |
| 1991-12-31 | $34.00 Million | $1.40 Million | 0.041x | -89.86% |
| 1990-12-31 | $12.80 Million | $5.20 Million | 0.406x | -- |
About CONMED Corporation
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation an… Read more